Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

Abstract Purpose To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. Methods We retrospectively screened 3807 patients diagnosed with cancer between 2013 and 2019 at...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chin‐Chou Wang, Chien‐Hao Lai, Yu‐Ping Chang, Huang‐Chih Chang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Meng‐Chih Lin
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	afatinib EGFR T790M mutation EGFR‐TKIs sequences erlotinib gefitinib osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/34581f760dc54df492d1a05b4f503c44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34581f760dc54df492d1a05b4f503c44
record_format	dspace
spelling	oai:doaj.org-article:34581f760dc54df492d1a05b4f503c442021-12-02T02:34:55ZComparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study1759-77141759-770610.1111/1759-7714.14198https://doaj.org/article/34581f760dc54df492d1a05b4f503c442021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14198https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Purpose To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. Methods We retrospectively screened 3807 patients diagnosed with cancer between 2013 and 2019 at Kaohsiung Chang Gung Memorial Hospital. In total, 76 patients with EGFR T790M mutation who received osimertinib after re‐biopsy or liquid biopsy were enrolled for the analysis. Results The median progression‐free survival (PFS), median overall survival (OS), and median OS2 of the 76 patients were 11.93, 66.53, and 29.57 months, respectively. A significant difference was observed in the disease control rate between those who received osimertinib treatment after chemotherapy (group A) and those who received osimertinib immediately following EGFR‐TKI therapy (group B) (34 [94.4%] vs. 31 [77.5%], p = 0.036). In addition, chronic obstructive pulmonary disease tended to be a poor prognostic factor for PFS and OS. Conclusion This real‐world analysis revealed that previous chemotherapy could affect the treatment outcomes of patients with non‐small cell lung cancer treated with osimertinib. Osimertinib treatment following first/second generation EGFR‐TKI treatment or chemotherapy resulted in improved survival benefit.Chin‐Chou WangChien‐Hao LaiYu‐Ping ChangHuang‐Chih ChangChia‐Cheng TsengKuo‐Tung HuangMeng‐Chih LinWileyarticleafatinibEGFR T790M mutationEGFR‐TKIs sequenceserlotinibgefitinibosimertinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3263-3272 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	afatinib EGFR T790M mutation EGFR‐TKIs sequences erlotinib gefitinib osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	afatinib EGFR T790M mutation EGFR‐TKIs sequences erlotinib gefitinib osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chin‐Chou Wang Chien‐Hao Lai Yu‐Ping Chang Huang‐Chih Chang Chia‐Cheng Tseng Kuo‐Tung Huang Meng‐Chih Lin Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
description	Abstract Purpose To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. Methods We retrospectively screened 3807 patients diagnosed with cancer between 2013 and 2019 at Kaohsiung Chang Gung Memorial Hospital. In total, 76 patients with EGFR T790M mutation who received osimertinib after re‐biopsy or liquid biopsy were enrolled for the analysis. Results The median progression‐free survival (PFS), median overall survival (OS), and median OS2 of the 76 patients were 11.93, 66.53, and 29.57 months, respectively. A significant difference was observed in the disease control rate between those who received osimertinib treatment after chemotherapy (group A) and those who received osimertinib immediately following EGFR‐TKI therapy (group B) (34 [94.4%] vs. 31 [77.5%], p = 0.036). In addition, chronic obstructive pulmonary disease tended to be a poor prognostic factor for PFS and OS. Conclusion This real‐world analysis revealed that previous chemotherapy could affect the treatment outcomes of patients with non‐small cell lung cancer treated with osimertinib. Osimertinib treatment following first/second generation EGFR‐TKI treatment or chemotherapy resulted in improved survival benefit.
format	article
author	Chin‐Chou Wang Chien‐Hao Lai Yu‐Ping Chang Huang‐Chih Chang Chia‐Cheng Tseng Kuo‐Tung Huang Meng‐Chih Lin
author_facet	Chin‐Chou Wang Chien‐Hao Lai Yu‐Ping Chang Huang‐Chih Chang Chia‐Cheng Tseng Kuo‐Tung Huang Meng‐Chih Lin
author_sort	Chin‐Chou Wang
title	Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
title_short	Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
title_full	Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
title_fullStr	Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
title_full_unstemmed	Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
title_sort	comparing survival and treatment response of patients with acquired t790m mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: a real‐world study
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/34581f760dc54df492d1a05b4f503c44
work_keys_str_mv	AT chinchouwang comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT chienhaolai comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT yupingchang comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT huangchihchang comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT chiachengtseng comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT kuotunghuang comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy AT mengchihlin comparingsurvivalandtreatmentresponseofpatientswithacquiredt790mmutationsecondlineosimertinibversussequentialtreatmentofchemotherapyfollowedbyosimertinibarealworldstudy
_version_	1718402341047107584

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

Ejemplares similares